Risk, responsibility, and generic drugs

New England Journal of Medicine

Volumn 367, Issue 18, 2012, Pages 1679-1681

  Kesselheim, Aaron S ^a   Avorn, Jerry ^a   Greene, Jeremy A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868238228     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1208781     Document Type: Article

References (5)

1. Glantz LH, Annas GJ. Impossible? Outlawing state safety laws for generic drugs. N Engl J Med 2011;365:681-3.
2. Thomas K. Generic drugs proving resistant to damage suits. New York Times. March 20, 2012.
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
4. Madigan D, Sigelman DW, Mayer JW, Furberg CD, Avorn J. Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. Am Heart J 2012;164:186-93.
5. Duke J, Friedlin J, Li X. Consistency in the safety labeling of bioequivalent medications. Pharmacoepidemiol Drug Saf (in press).